Kopenmaar! schreef op 31 maart 2011 19:43:
“Without a better tolerated interferon, these new triple and quad combinations will carry huge
tolerability challenges that will limit access to care, reduce treatment intent rates and likely cause
poor adherence in a real-world setting which we know lowers cure rates and raises the risk of
multi-drug resistance,” Turek further explained. “Our goal as we move into Phase 3 is to
leverage Locteron’s clear advantages in tolerability, combinability and dosing to position it along
with the best direct-acting anti-virals to set the new standard in combination therapy for hepatitis
C.”
van biolex.com,
hier staat toch echt dat we naar FASE III gaan!